Randomized Study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid (HN001)

Randomized Study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid (HN001)

Trial Category:
Head and Neck
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE

This study is looking at tumors in the Nasal or Nose and back of throat area. Treatment is based on various tumor characteristics.  Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study treatment options using the same criteria in order to identify if one treatment may be superior to another treatment. 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members